An international round-table called Possibilities and Difficulties in Global Biomarkets, has also been confirmed. Its primary goal is to discuss today’s state of the biotechnological market, its development, and its own future prospects. Probably the most attractive aspects of BioSpain 2010 may be the chance for networking, with over 1,200 delegates from 650 companies & institutions expected to go to. Furthermore, the investors’ forum seeks to find brand-new financing sources for upcoming entrepreneurial projects. 30 companies will show their business intend to an audience of specialists and investors, including representatives of Merck & Co, Bay City Capital, La Caixa, Ysios Capital Partners, GlaxoSmithKline Pharmaceuticals, Forbion Capital Partners, Suanfarma Biotech, McKinsey & Company, and PharmaVentures.